EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Australian Gonococcal Surveillance Program, 1 January to 31 March 2025

Monica Lahra, Sebastiaan Van Hal, Tiffany Hogan

Communicable Diseases Intelligence · 2025

DOI: 10.33321/cdi.2025.49.046 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Communicable Diseases Intelligence, 2025. Verfasst von Monica Lahra und 2 weiteren Autor:innen. Beteiligte Einrichtung: The World Health Organization Collaborating Centre for STI and AMR and Neisseria Reference Laboratory, NSW Health Pathology, Microbiology, Prince of …. Hauptthemen laut MEDLINE: Gonorrhea, Neisseria gonorrhoeae, Anti-Bacterial Agents. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The National Neisseria Network (NNN), Australia, established in 1979, comprises reference laboratories in each state and territory. Since 1981, the NNN has reported data for the Australian Gonococcal Surveillance Programme (AGSP), on antimicrobial susceptibility profiles for Neisseria gonorrhoeae isolated from each jurisdiction for an agreed group of agents. The antibiotics reported represent current or potential agents used for the treatment of gonorrhoea, and include ceftriaxone, azithromycin, ciprofloxacin and penicillin. More recently, gentamicin and tetracycline are included in the AGSP Annual Report. Ceftriaxone, combined with azithromycin, is the recommended treatment regimen for gonorrhoea in Australia. Historically, there were substantial geographic differences in susceptibility patterns across the country, with certain remote regions of the Northern Territory and Western Australia having low gonococcal antimicrobial resistance rates. In these regions, an oral treatment regimen comprising amoxycillin, probenecid, and azithromycin was recommended. However, since January 2023, increasing reports of penicillin-resistant N. gonorrhoeae in the Northern Territory have changed treatment recommendations to align with the majority of Australia.1 Additional data on other antibiotics are reported in the AGSP Annual Report. The AGSP has a programme-specific quality assurance process.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

GonorrheaNeisseria gonorrhoeaeAnti-Bacterial AgentsHumansAustraliaMicrobial Sensitivity TestsDrug Resistance, BacterialPopulation SurveillanceAzithromycinEpidemiological MonitoringCeftriaxone

Stichwörter der Autor:innen

Neisseria gonorrhoeaeantimicrobial resistancedisease surveillancegonococcal infection

Substanzen

Anti-Bacterial AgentsAzithromycinCeftriaxone

Autor:innen und Institutionen

  • The World Health Organization Collaborating Centre for STI and AMR and Neisseria Reference Laboratory, NSW Health Pathology, Microbiology, Prince of Wales Hospital, Randwick, NSW 2031, Australia; School of Medical Scien…
  • Molecular Microbiology, Royal Prince Alfred Hospital, Camperdown, NSW 2050, Australia.

Zitieren

APA

Lahra, M., Van Hal, S., & Hogan, T. (2025). Australian Gonococcal Surveillance Program, 1 January to 31 March 2025. Communicable Diseases Intelligence. https://doi.org/10.33321/cdi.2025.49.046

Vancouver

Lahra M, Van Hal S, Hogan T. Australian Gonococcal Surveillance Program, 1 January to 31 March 2025. Communicable Diseases Intelligence. 2025. doi:10.33321/cdi.2025.49.046

BibTeX
@article{Lahra2025,
  author = {Lahra, Monica and Van Hal, Sebastiaan and Hogan, Tiffany},
  title = {Australian Gonococcal Surveillance Program, 1 January to 31 March 2025},
  journal = {Communicable Diseases Intelligence},
  year = {2025},
  doi = {10.33321/cdi.2025.49.046}
}
Kostenlos starten →